Sectors
VKTX
Viking Therapeutics, Inc.
31.98
1 x 31.98
3 x 32.00
bid
ask
-
0.17
0.54%
10:30 AM
timesize
| Ytd | -9.08% | |
| 1y | 18.24% |
31.70
day range
32.10
22.96
52 week range
43.15
| Open | 31.77 | Prev Close | 32.16 | Low | 31.70 | High | 32.10 | Mkt Cap | 3.74B |
| Vol | 220.65K | Avg Vol | 2.27M | EPS | -4.67 | P/E | N/A | Forward P/E | -7.45 |
| Beta | 0.69 | Short Ratio | 11.73 | Inst. Own | 66.12% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-28 | 50-d Avg | 35.50 | 200-d Avg | 33.65 | 1yr Est | 92.39 |
| Income Statement | |||
| Operating Expenses | 132.60M | ||
| Research and Development Expense | 115.75M | ||
| Selling, General and Administrative Expense | 16.84M | ||
| Operating Income | -132.60M | ||
| Net Income | -128.02M | ||
| Net Income Common Stock | -128.02M | ||
| Net Income Common Stock (USD) | -128.02M | ||
| Consolidated Income | -128.02M | ||
| Earnings per Basic Share | -1.10 | ||
| Earnings per Basic Share (USD) | -1.10 | ||
| Earnings per Diluted Share | -1.10 | ||
| Earning Before Interest & Taxes (EBIT) | -128.02M | ||
| Earning Before Interest & Taxes (USD) | -128.02M | ||
| Weighted Average Shares | 116.26M | ||
| Weighted Average Shares Diluted | 116.26M | ||
| Balance Sheet | |||
| Cash and Equivalents | 126.07M | ||
| Cash and Equivalents (USD) | 126.07M | ||
| Investments | 375.91M | ||
| Investments Current | 375.91M | ||
| Current Assets | 517.56M | ||
| Property, Plant & Equipment Net | 4.01M | ||
| Total Assets | 521.90M | ||
| Debt Current | 161.00K | ||
| Total Debt | 4.09M | ||
| Current Liabilities | 109.66M | ||
| Debt Non-Current | 3.93M | ||
| Total Liabilities | 113.58M | ||
| Accumulated Retained Earnings (Deficit) | -1.13B | ||
| Accumulated Other Comprehensive Income | -1.15M | ||
| Shareholders Equity | 408.32M | ||
| Shareholders Equity (USD) | 408.32M | ||
| Assets Non-Current | 4.33M | ||
| Total Debt (USD) | 4.09M | ||
| Liabilities Non-Current | 3.93M | ||
| Trade and Non-Trade Payables | 69.01M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 157.00K | ||
| Net Cash Flow from Financing | 23.59M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 7.85M | ||
| Issuance (Purchase) of Equity Shares | 23.59M | ||
| Net Cash Flow from Investing | 109.43M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 109.43M | ||
| Net Cash Flow from Operations | -125.17M | ||
| Share Based Compensation | 11.13M | ||